Code of Maine Rules › 10 - DEPARTMENT OF HEALTH AND HUMAN SERVICES › 144 - DEPARTMENT OF HEALTH AND HUMAN SERVICES - GENERAL › Chapter 258 - RULES FOR THE CONTROL OF NOTIFIABLE DISEASES AND CONDITIONS › Appendix A - NOTIFIABLE DISEASES AND CONDITIONS LIST

Current through 2024-29, July 17, 2024
* Category I Diseases must be reported to the Department
immediately.
** Category II Diseases must be reported within
48
				  hours of
the diagnosis or laboratory test result.
# Laboratories are to submit isolates or clinical specimens
				  for the following, as well as any isolates or clinical specimens, as requested
				  by HETL for confirmation, typing and/or antibiotic sensitivity.
Table 1.
Notifiable Diseases and
							 Conditions
Disease or Condition
Agent
**
Acquired immunodeficiency syndrome (AIDS)
Human immunodeficiency virus
**
Acute flaccid myelitis
							 (AFM)1
**
Anaplasmosis
Anaplasmaphagocytophilum
*
#
Anthrax
Bacillus anthracis
**
Babesiosis
Babesia microti
*
#
Botulism
Clostridium botulinum
**
Borrelia miyamotoi
Borrelia miyamotoi
*
#
Brucellosis
Brucella
species
**
California serogroup viruses
**
Campylobacteriosis
Campylobacter
species
*
#
Candida auris2
Candida auris
*
#
Carbapenemase-producing carbapenem-resistant
							 organisms3
Enterobacteriaceae
spp.
Pseudomonas aeruginosa (non-mucoid
							 only)
Acinetobacter baumannii
**
Carbon monoxide
							 poisoning4
Carbon monoxide
**
Chancroid
Haemophilusducreyi
**
Chlamydia
Chlamydia trachomatis
**
Chickenpox (varicella)
Varicella-zoster virus
**
Chikungunya
Chikungunya virus
*
#
Coronavirus (novel,
MERS, and
							 SARS
)
Coronavirus
**
Creutzfeldt-Jakob disease, < 55 years of
							 age
Creutzfeldt-Jakob agent
**
Cryptosporidiosis
Cryptosporidium
species
**
Cyclosporiasis
Cyclospora
**
Dengue
Dengue fever virus
Disease or Condition
Agent
*
#
Diphtheria
Corynebacterium diphtheriae
**
#
E.coli, Shiga toxin-producing (STEC)
Escherichia coli
, Shiga
							 toxin-producing
**
Eastern equine encephalitis
Eastern equine encephalitis virus
**
Ehrlichiosis
Ehrlichia
species
**
Giardiasis
Giardia
species
**
Gonorrhea
Neisseria gonorrhoeae
**
#
Haemophilus influenzae,invasive
Haemophilus influenzae
**
Hantavirus, pulmonary and non-pulmonary
							 syndromes
Hantavirus
**
Hemolytic-uremic syndrome (post-diarrheal)
Escherichia coli
, Shiga
							 toxin-producing
*
Hepatitis A, B, C, D, E (acute)
Hepatitis A, B, C, D, E viruses
**
Hepatitis B, C, D (chronic)
Hepatitis B, C, D viruses
**
Human immunodeficiency virus
							 (HIV)5
Human immunodeficiency virus
**
Influenza-associated pediatric death
Influenza virus
*
#
Influenza A, novel
Influenza virus
**
Influenza-associated hospitalizations,
							 laboratory-confirmed
Influenza virus
**
Legionellosis
Legionella
species
**
Leptospirosis
Leptospira
species
**
#
Listeriosis
Listeria monocytogenes
**
Lyme disease
Borrelia burgdorferi
**
Malaria
Plasmodium
species
*
#
Measles
Rubeola virus
*
#
Meningococcal disease, invasive
Neisseria meningitidis
*
#
Mumps
Mumps virus
*
Pertussis
Bordetella pertussis
*
#
Plague
Yersinia pestis
*
#
Poliomyelitis
Poliovirus
**
Powassan
Powassan or deer tick virus
**
Psittacosis
Chlamydia psittaci
*
Q fever
Coxiella burnetii
*
#
Rabies (human and animal)
Rabies virus
**
Rabies post-exposure prophylaxis
*
#
Ricin poisoning
*
#
Rubella (including congenital)
Rubella virus
**
#
Salmonellosis
Salmonella
species
*
Shellfish poisoning
**
#
Shigellosis
Shigella
species
*
#
Smallpox
Variola virus
**
Spotted fever rickettsiosis
Rickettsia rickettsii
Disease or Condition
Agent
**
St. Louis encephalitis
St. Louis encephalitis virus
*
#
Staphylococcus aureus non-susceptible to
							 vancomycin6
Staphylococcus aureus
**
Streptococcus group A, invasive
Streptococcus pyogenes
(group A beta
							 hemolytic strep)
**
Streptococcus pneumoniae, invasive
Streptococcus pneumoniae
**
Syphilis
Treponema pallidum
*
#
Tetanus
Clostridium tetani
**
Trichinosis
Trichinella
species
*
#
Tuberculosis (active and presumptive)
Mycobacterium tuberculosis
*
#
Tularemia
Francisellatularensis
**
#
Vibrio species, including cholera
Vibrio
species
**
Vaping-associated pulmonary
							 illness7
*
Viral hemorrhagic fever
Arenaviruses and others
**
West nile
West nile virus
**
Western equine encephalitis
Western equine encephalitis virus
**
Yellow fever
Yellow fever virus
**
Zika virus disease
Zika virus
*
Any case of unusual illness of infectious
							 cause
*
Any cluster/outbreak of illness with potential public
							 health significance
1 An illness with an onset of
				  acute focal limb weakness and either 1) cerebrospinal fluid with an elevated
				  white blood cell count or 2) a magnetic resonance image (MRI) showing a spinal
				  cord lesion largely restricted to gray matter and spanning one or more spinal
				  segments.
2 Detection of
Candida
				  auris
in a specimen using culture or culture independent diagnostic
				  test; or detection of an organism that commonly represents a
Candida
				  auris
misidentification.
3 Carbapenemase-producing
				  carbapenem-resistant organisms are:
* Carbapenem-resistant organisms, as defined by the Clinical
				  Laboratory Standards Institute Performance Standards for Antimicrobial
				  Susceptibility Testing M100 (
http://www.clsi-m100.com
), that test
				  positive for Carbapenemase-producing by a phenotype method or for a known
				  carbapenemase resistance mechanisms by a recognized test, as defined by the
				  U.S. Centers for Disease Control and Prevention (
https://wwwn.cdc.gov/nndss/conditions/carbapenemase-producing-carbapenem-resistant-enterobacteriaceae/case-definition/2018/
).
* Reporting will include test method used, result, and where
				  applicable, specific resistance mechanisms identified.
* Isolate submission is required for all carbapenem-producing
				  carbapenem-resistant organisms. If phenotypic or resistance mechanism test
				  results are not available for a carbapenem-resistant organism, then isolate
				  submission of the carbapenem-resistant organism is required to determine
				  carbapenemase-producing status.
4 All cases with clinical signs,
				  symptoms or known exposure consistent with diagnosis of carbon monoxide
				  poisoning, and/or: a carboxyhemoglobin (COHb) level equal to or above
				  5%.
5Any human immunodeficiency virus
				  (HIV) test results, including:
* All reactive/repeatedly reactive initial HIV immunoassay
				  results and all results (e.g. positive, negative, indeterminate) from all
				  supplemental HIV immunoassays (HIV-1/2 antibody differentiation assay, HIV-1
				  Western blot, HIV-2 Western blot or HIV-1 Immunofluorescent assay);
* All HIV nucleic acid (RNA or DNA) detection tests
				  (qualitative and quantitative), including tests on individual specimens for
				  confirmation of nucleic acid amplification testing (NAAT) screening
				  results;
* All CD4 lymphocyte counts and percentages, unless known to
				  be ordered for a condition other than HIV;
* HIV genotypic resistance testing, nucleotide sequence
				  results; and,
* Positive HIV detection tests (including, but not limited to
				  culture, P24 antigen).
6 As defined by the most current
				  Clinical Laboratory Standards Institute Performance Standards for Antimicrobial
				  Susceptibility Testing M100 (
http://www.clsi-m100.com
).
7 Clinicians should report cases
				  with onset on or after May 1, 2019, that meet the criteria of (1) a significant
				  respiratory illness of unclear etiology and (2) a history of
				  vaping.